Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology.
about
Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumorsAction and Traction: Cytoskeletal Control of Receptor Triggering at the Immunological SynapseMolecular therapeutics in pancreas cancerImmunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trialsBlood transcriptomics and metabolomics for personalized medicineAnti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic ApproachesExercise in Regulation of Inflammation-Immune Axis Function in Cancer Initiation and ProgressionGrand challenges in space synthetic biologyChimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall StreetSynthetic therapeutic gene circuits in mammalian cellsDendritic Cell Therapy in an Allogeneic-Hematopoietic Cell Transplantation Setting: An Effective Strategy toward Better Disease Control?Adoptive T-cell therapy for LeukemiaCancer vaccinesImmune escape mechanisms as a guide for cancer immunotherapyAdoptive cell therapies for glioblastomaLarge molecular systems landscape uncovers T cell trapping in human skin cancer.A biased competition theory of cytotoxic T lymphocyte interaction with tumor nodulesSelective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptorAntigen-specific T cells fully conserve antitumour function following cryopreservation.Melanoma cell lysosome secretory burst neutralizes the CTL-mediated cytotoxicity at the lytic synapseRemote control of therapeutic T cells through a small molecule-gated chimeric receptor.Individual Motile CD4(+) T Cells Can Participate in Efficient Multikilling through Conjugation to Multiple Tumor Cells.Combination Approaches with Immune-Checkpoint Blockade in Cancer TherapyHigh-content molecular profiling of T-cell therapy in oncologyTargeted immune therapy of ovarian cancerCish actively silences TCR signaling in CD8+ T cells to maintain tumor toleranceChimeric antigen receptor T cells for sustained remissions in leukemiaPI3K and cancer: lessons, challenges and opportunitiesRestoring the balance: immunotherapeutic combinations for autoimmune diseaseFusions of Tumor-derived Endothelial Cells with Dendritic Cells Induces Antitumor Immunity.Inflammation and Epithelial-Mesenchymal Transition in Pancreatic Ductal Adenocarcinoma: Fighting Against Multiple OpponentsIn vivo discovery of immunotherapy targets in the tumour microenvironment.Engineered chimeric antigen receptor-expressing T cells for the treatment of pancreatic ductal adenocarcinoma.Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNγ.Oncolytic measles virus enhances antitumour responses of adoptive CD8+NKG2D+ cells in hepatocellular carcinoma treatment.Rescue of notch-1 signaling in antigen-specific CD8+ T cells overcomes tumor-induced T-cell suppression and enhances immunotherapy in cancerICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.Bioactive compounds or metabolites from black raspberries modulate T lymphocyte proliferation, myeloid cell differentiation and Jak/STAT signaling.Engineered T cells for cancer therapy.Natural killer cells eradicate galectin-1-deficient glioma in the absence of adaptive immunity.
P2860
Q26741260-49475DDB-DBC0-4033-8418-47183847172EQ26751049-1B85517B-68EE-4838-A3BE-62D818EC3807Q26751709-A0025A50-1596-41FE-A4DA-328FEDAB8DB3Q26765115-C1DB1AEB-28BC-4DC1-B1E3-E754E65A3AF8Q26772073-C076A07E-D913-4928-A1C6-EB944C2BF116Q26774312-059FD65B-A936-40EA-BF6F-4946B6E95709Q26775189-9CD711F1-355C-4C28-951B-1D6250F81F5BQ26775307-68B2740F-F1DA-4639-878D-55A7DD5BA79EQ26799357-36E4AFA4-5BAF-4E58-B9A4-1272CB580C39Q26826954-33E89425-A39B-4C72-B50F-0F0972AE515DQ26830857-2C1F63FC-B1F7-4A1B-BFA2-1350E748C58CQ27006934-35153D9F-512B-4A35-AC64-FB2C5507F224Q27024438-7FE5D59D-D382-4AC7-8149-CBDC0D547867Q27024502-32FCA4DF-033B-4827-A64F-712643D7E55AQ27030863-62896BC4-3BD2-4421-B654-9A45A5C69B50Q27302197-4B0C7C64-6378-41B1-8F67-577812574155Q27311561-6105297E-1CA6-47D9-A01A-F6A4722BEDFFQ27318470-A39A19EC-C048-4911-86AB-70F95B77F133Q27323082-F4F48A2F-2CF0-4E58-926E-331B02114539Q27329598-96EA646E-3E27-406A-9F00-70DCDBC9DED0Q27330599-4FB00442-6520-4FC0-9102-3639E429179FQ27345402-6D74577A-506C-49D5-94DF-51DCA4843AC7Q28066199-AC6506A0-CAC3-490F-8831-C5852F6DCE50Q28066792-6C3B6DC4-CB74-4BB1-9A8B-390066715947Q28082828-02200721-71E9-4594-9C79-2658F6FAC146Q28269352-4A3C1950-7776-4809-AE59-5A2AB525FE34Q29617588-107493B1-391A-4385-8015-FA72EC89584AQ30080017-0E6B6C63-49B0-493F-9F6F-69923F1B60EDQ33555986-DF4EC2DB-36AC-465D-9C6B-7A69A77A89E2Q33594333-9FC77589-C72E-446D-8032-2C4C2814A7B1Q33704284-1825FB87-A28F-4F00-8C24-471B9DD1A993Q33736396-E092C308-7127-4522-A50D-156D7736B6B7Q33776367-E47676B9-F7C3-4486-8DD5-B84907AA85F9Q33776925-DE878B25-5645-4376-8C53-DAB1A487A579Q33899522-3E6C7C28-2005-4739-AE69-10944D7C0EFDQ34017104-9561BB44-128B-4D06-BD1C-755228AB5D36Q34047847-25E620C9-DCD1-40F0-B535-C032084A3548Q34079557-2949AA16-CB9B-4DC0-B85A-5AD668DBA84FQ34080368-48DD597D-B851-4A55-BF13-69493FEE4480Q34287535-0D1A00F2-F612-4176-9877-565578A8901E
P2860
Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology.
@en
Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology.
@nl
type
label
Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology.
@en
Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology.
@nl
prefLabel
Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology.
@en
Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology.
@nl
P2860
P1433
P1476
Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology.
@en
P2093
Carl H June
Michael Kalos
P2860
P356
10.1016/J.IMMUNI.2013.07.002
P407
P577
2013-07-01T00:00:00Z